Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Back In The Game: One Year After Rx Exit, P&G Signs On To Promote Silenor

This article was originally published in The Pink Sheet Daily

Executive Summary

Somaxon and P&G are preparing to launch the insomnia drug in September with a combined sales force of 215 reps.

You may also be interested in...



Somaxon's Silenor Gains An FDA Approval, But Can The Pharma Afford A Launch?

Somaxon hopes to launch its insomnia drug in the second half of 2010, but is still searching for a U.S. commercial partner.

Somaxon Sleep Aid Silenor Not Effective, FDA Says

In its second "complete response" letter for the chronic insomnia drug, FDA says Silenor fails to meet approval standards.

P&G Throws Weight Behind Consumer Growth After Shedding Pharma

Since many of its key consumer product lines are already mature U.S. brands, Procter & Gamble will have to drive growth by expanding into new markets and acquiring either hard-to-find licenses for OTC switch candidates or existing nonprescription brands.

Related Content

Topics

UsernamePublicRestriction

Register

PS071084

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel